TrialThe oncologist2017

Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.

Yehuda Patt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.